Trial Profile
Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Dordaviprone (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; First in man
- 19 Nov 2020 Status changed from recruiting to discontinued.
- 05 Jun 2019 Planned End Date changed from 1 Nov 2022 to 1 Nov 2021.
- 22 May 2019 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.